Trial Search Results
A Study of an Investigational V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults (V212-002)
This study will evaluate the safety and immunogenicity of a heat-treated VZV vaccine in autologous or allogeneic hematopoietic cell transplant (HCT) recipients, human immunodeficiency virus (HIV)-infected participants with a baseline cluster of differentiation 4 (CD4) cell count ≤200 cells/mm^3, participants with solid tumor malignancy (STM; breast, colorectal, lung, or ovarian malignancies) receiving chemotherapy, and participants with hematologic malignancy (HM; leukemia or leukemia-like disease, lymphoma or lymphoma-like disease, or multiple myeloma). The primary hypothesis is that the heat-treated VZV vaccine will elicit significant VZV-specific immune responses measured by either glycoprotein-based enzyme-linked immunosorbent assay (gpELISA) or VZV gamma interferon enzyme-linked immunospot (IFN-ELISPOT) at 28 days post dose vaccination 4 in, HIV-infected participants, participants with STM, and participants with HM. The primary immunogenicity objective and endpoints were considered by the protocol as exploratory for the autologous and allogeneic HCT groups.
Stanford is currently not accepting patients for this trial.
Merck Sharp & Dohme Corp.
- Biological: V212
- Biological: Placebo
- Men and women > or = to 18 years of age who are scheduled to receive an autologous or
allogeneic hematopoietic cell transplant within 60 days of enrollment
- HIV-infected participants with a baseline CD4 cell count < or = to 200 cells/mm^3
- Participants with hematologic malignancies; or participants who are receiving
chemotherapy for breast, colorectal, lung, or ovarian malignancies
- History of allergy to any vaccine component
- Prior history of HZ
- Prior history of receipt of any varicella or zoster vaccine
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study